These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22711801)

  • 1. Identifying mechanism-of-action targets for drugs and probes.
    Gregori-Puigjané E; Setola V; Hert J; Crews BA; Irwin JJ; Lounkine E; Marnett L; Roth BL; Shoichet BK
    Proc Natl Acad Sci U S A; 2012 Jul; 109(28):11178-83. PubMed ID: 22711801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of TTD: Therapeutic Target Database.
    Zhu F; Han B; Kumar P; Liu X; Ma X; Wei X; Huang L; Guo Y; Han L; Zheng C; Chen Y
    Nucleic Acids Res; 2010 Jan; 38(Database issue):D787-91. PubMed ID: 19933260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DrugE-Rank: improving drug-target interaction prediction of new candidate drugs or targets by ensemble learning to rank.
    Yuan Q; Gao J; Wu D; Zhang S; Mamitsuka H; Zhu S
    Bioinformatics; 2016 Jun; 32(12):i18-i27. PubMed ID: 27307615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting new molecular targets for known drugs.
    Keiser MJ; Setola V; Irwin JJ; Laggner C; Abbas AI; Hufeisen SJ; Jensen NH; Kuijer MB; Matos RC; Tran TB; Whaley R; Glennon RA; Hert J; Thomas KL; Edwards DD; Shoichet BK; Roth BL
    Nature; 2009 Nov; 462(7270):175-81. PubMed ID: 19881490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical probes for biological systems.
    Garcia-Serna R; Mestres J
    Drug Discov Today; 2011 Feb; 16(3-4):99-106. PubMed ID: 21093609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network analysis of FDA approved drugs and their targets.
    Ma'ayan A; Jenkins SL; Goldfarb J; Iyengar R
    Mt Sinai J Med; 2007 Apr; 74(1):27-32. PubMed ID: 17516560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting new indications for approved drugs using a proteochemometric method.
    Dakshanamurthy S; Issa NT; Assefnia S; Seshasayee A; Peters OJ; Madhavan S; Uren A; Brown ML; Byers SW
    J Med Chem; 2012 Aug; 55(15):6832-48. PubMed ID: 22780961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From knowing to controlling: a path from genomics to drugs using small molecule probes.
    Strausberg RL; Schreiber SL
    Science; 2003 Apr; 300(5617):294-5. PubMed ID: 12690189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories.
    Re M; Valentini G
    IEEE/ACM Trans Comput Biol Bioinform; 2013; 10(6):1359-71. PubMed ID: 24407295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network.
    Daminelli S; Haupt VJ; Reimann M; Schroeder M
    Integr Biol (Camb); 2012 Jul; 4(7):778-88. PubMed ID: 22538435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in exploration of therapeutic targets.
    Zheng CJ; Han LY; Yap CW; Xie B; Chen YZ
    Drug News Perspect; 2005 Mar; 18(2):109-27. PubMed ID: 15883620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of electron paramagnetic resonance (EPR) spectroscopy and imaging in drug delivery research - chances and challenges.
    Kempe S; Metz H; Mäder K
    Eur J Pharm Biopharm; 2010 Jan; 74(1):55-66. PubMed ID: 19723580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mapping of drug space from the viewpoint of small molecule metabolism.
    Adams JC; Keiser MJ; Basuino L; Chambers HF; Lee DS; Wiest OG; Babbitt PC
    PLoS Comput Biol; 2009 Aug; 5(8):e1000474. PubMed ID: 19701464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MMsINC: a large-scale chemoinformatics database.
    Masciocchi J; Frau G; Fanton M; Sturlese M; Floris M; Pireddu L; Palla P; Cedrati F; Rodriguez-Tomé P; Moro S
    Nucleic Acids Res; 2009 Jan; 37(Database issue):D284-90. PubMed ID: 18931373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-basic estimates the size of druggable human genome.
    Plewczynski D; Rychlewski L
    J Mol Model; 2009 Jun; 15(6):695-9. PubMed ID: 18663489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathway analysis for design of promiscuous drugs and selective drug mixtures.
    Sivachenko A; Kalinin A; Yuryev A
    Curr Drug Discov Technol; 2006 Dec; 3(4):269-77. PubMed ID: 17430103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying unexpected therapeutic targets via chemical-protein interactome.
    Yang L; Chen J; Shi L; Hudock MP; Wang K; He L
    PLoS One; 2010 Mar; 5(3):e9568. PubMed ID: 20221449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates.
    Jónsdóttir SO; Jørgensen FS; Brunak S
    Bioinformatics; 2005 May; 21(10):2145-60. PubMed ID: 15713739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the exploitation of novel drug targets.
    Rask-Andersen M; Almén MS; Schiöth HB
    Nat Rev Drug Discov; 2011 Aug; 10(8):579-90. PubMed ID: 21804595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.